*January 2021*

Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and platinum (EP) in untreated extensive-stage small cell lung cancer (ES-SCLC), cementing checkpoint inhibition plus chemotherapy as a frontline standard, explained Yanyan Lou, MD, PhD.

IMpower133 was the first phase 3 trial to test the addition of a checkpoint inhibitor to chemotherapy in the first-line setting in ES-SCLC. Patients with untreated ES-SCLC were randomized to atezolizumab plus EP for 4 cycles followed by maintenance atezolizumab or placebo plus EP for 4 cycles followed by placebo maintenance. Read more.